



ABN: 15 129 742 409

dorsaVi Share Purchase Plan

Melbourne, Australia – 30 December 2019: dorsaVi Ltd (ASX: DVL) (**dorsaVi** or **Company**) confirms that dorsaVi's Share Purchase Plan (**SPP**) announced to the market on 28 November 2019 and which closed at 7.00pm on 19 December 2019, has raised \$186,760 from eligible shareholders.

dorsaVi announced on 28 November 2019 that it had secured additional funding of approximately \$1.7 million from placements of convertible notes and shares to existing and new institutional and sophisticated investors, \$0.36million of which will be subject to shareholder approval. As previously advised, the Company has called a general meeting for 28 January 2020 to approve this placement and the issue of shares to convertible noteholders on conversion of their notes.

The total funds raised (assuming shareholder approval is obtained) (before costs) of \$1.9 million, will be used for general working capital purposes and to assist the Company's push into the United States market.

The key dates follow below:

- the SPP allotment date of new fully paid ordinary shares (**New Shares**) is today, 30 December 2019; and
- holding statements will be despatched on or around 31 December 2019.

The New Shares issued under the SPP will rank equally with the Company's existing ordinary shares.

Andrew Ronchi
Chief Executive Officer

For more information about dorsaVi or to arrange an interview, please contact:

MEDIA
Megan Connell
dorsaVi
0416 116 526
mconnell@dorsavi.com

About dorsaVi

dorsaVi (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified, and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions - ViMove, ViMove2 and Professional Suite – which provide objective assessment, monitoring outside the clinic and immediate biofeedback. dorsaVi is currently used by medical and physiotherapy practices globally.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used in the US by the National Basketball Association (NBA), the Major Soccer League (MLS) and the National Football League (NFL), by the AFL and NRL clubs, Cricket Australia, and the Australian Institute of Sport (AIS) in Australia, and by Barclays Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally.
- **OHS:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton.

Further information is available at www.dorsavi.com.